## **Core Concept**
Humoral graft rejection, also known as antibody-mediated rejection, is a type of immune response against a transplanted organ. It involves the production of antibodies by B cells against antigens present on the graft, leading to activation of the complement system and damage to the graft. This process is primarily mediated by pre-formed or de novo antibodies.

## **Why the Correct Answer is Right**
The correct answer involves the activation of complement and the presence of antibodies against the graft. Humoral rejection is characterized by the binding of antibodies to antigens on the endothelial cells of the graft's blood vessels, leading to complement activation, inflammation, and thrombosis. This results in graft dysfunction or failure. The key players in this process include B cells producing antibodies and the complement system.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might mention cell-mediated immunity, which is incorrect because humoral rejection specifically involves antibodies and complement, not T cell-mediated cytotoxicity.
- **Option B:** If this option suggests a role for natural killer cells, it would be incorrect because, although NK cells can be involved in graft rejection, humoral rejection is specifically mediated by antibodies.
- **Option C:** If this option refers to a different immune pathway, such as a cell-mediated response, it would be incorrect for the reasons mentioned above.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that humoral graft rejection can occur immediately or even years after transplantation. It is often associated with the presence of donor-specific antibodies (DSAs), and its diagnosis involves detecting these antibodies and evidence of graft damage. A high index of suspicion and monitoring for DSAs are crucial in preventing and managing this condition.

## **Correct Answer:** D. Humoral graft rejection is characterised by the presence of circulating antibodies against the graft.